ALGS
Aligos TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
ALGS vs peer average
82/100
ALGS vs. peer average (A vs. C)
Grade spread
A 1 · B 3 · C 3 · D 3 · F 1
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ABUS is the first available peer comparator.
Arbutus is a relevant HBV therapeutic peer because Aligos lists Arbutus among companies with oligonucleotide agents in clinical development for chronic HBV infection; modality differs, but the clinical disease area and competitive investor narrative overlap [#10-K-2026-03-05].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ALGS
Aligos Therapeutics
ABUS
Arbutus Biopharma
Grade
A
B
Momentum
65
54
Value
57
41
Sentiment
64
77
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ABUS
ALGS / ABUS
Grade Position
Above peers
ALGS vs. peer average (A vs. C)
82/100
Momentum
65
ALGSValue
57
ALGSSentiment
64
ABUSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ALGS
ABUS is the first peer returned for this comparison set.